Foundry Partners’s CareDx CDNA Stock Holding History

Foundry Partners’s Portfolio CDNA Stock Details CDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-23,843	Closed	-$1.62M	–	384
2021 Q1	$1.62M	Sell	23,843 -10,938	-31%	-$849K	0.05%	308
2020 Q4	$2.52M	Buy	+34,781	New	+$2.02M	0.1%	249

Other funds holding CDNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Foundry Partners's CDNA Position: Q2 2021 in Review

Foundry Partners sold out of CareDx (CDNA) in Q2 2021, closing a stake of 23,843 shares — an estimated $1.62M sold.

Foundry Partners first reported a position in CDNA in Q4 2020 and held it in 2 quarters. The position peaked at $2.52M in Q4 2020. 254 funds tracked by Wall St. Rank hold CDNA as of Q2 2021.

Foundry Partners reported no remaining CareDx position as of Q2 2021 after selling out during the quarter.
Foundry Partners sold 23,843 CareDx shares in Q2 2021, an estimated $1.62M.
Foundry Partners first reported a position in CareDx in Q4 2020 and held it in 2 quarters.
Foundry Partners's CareDx position peaked at $2.52M in Q4 2020.
254 funds tracked by Wall St. Rank held CareDx as of Q2 2021.

Based on Foundry Partners's 13F filing for Q2 2021, filed 23 Jul 2021.